Literature DB >> 2274922

The binding of phosphatidylglycerol liposomes to rat platelets is mediated by complement.

H C Loughrey1, M B Bally, L W Reinish, P R Cullis.   

Abstract

Previous work has shown that intravenous administration of phosphatidylglycercol (PG) containing liposomes to rats results in a rapid transient decline in platelet count (1). Here the interactions of PG liposomes with rat platelets in vitro have been examined with the aim of characterizing factors associated with the decline. It is shown that PG liposomes induce formation of rat (but not human) platelet-liposome microaggregates in vitro. The PG liposome dependent thrombocytopenia observed in vivo can therefore be attributed to sequestration of PG liposome-platelet aggregates. Further, the aggregation of platelets with PG liposomes, which can be monitored as a reduction in platelet count using a coulter counter, is shown to be mediated by a serum complement factor, likely C3b. This is indicated by a requirement of plasma for the in vitro reduction in platelet count induced by PG liposomes, and the inhibition of this effect by heat treatment of plasma, by incubation of plasma with purified cobra venom factor, or by removal of C3 from plasma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2274922

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups.

Authors:  S M Moghimi; A C Hunter
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

Review 2.  Immunological risk of injectable drug delivery systems.

Authors:  Wim Jiskoot; Rianne M F van Schie; Myrra G Carstens; Huub Schellekens
Journal:  Pharm Res       Date:  2009-02-27       Impact factor: 4.200

3.  Post-modification of preformed liposomes with novel non-phospholipid poly(ethylene glycol)-conjugated hexadecylcarbamoylmethyl hexadecanoic acid for enhanced circulation persistence in vivo.

Authors:  Okhil K Nag; Vivek R Yadav; Andria Hedrick; Vibhudutta Awasthi
Journal:  Int J Pharm       Date:  2013-02-16       Impact factor: 5.875

4.  Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2',3'-dideoxyinosine.

Authors:  P Harvie; A Désormeaux; M C Bergeron; M Tremblay; D Beauchamp; L Poulin; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  Monosialoganglioside GM1 shortens the blood circulation time of liposomes in rats.

Authors:  D Liu; F Liu; Y K Song
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

6.  Biological evaluation of liposome-encapsulated hemoglobin surface-modified with a novel PEGylated nonphospholipid amphiphile.

Authors:  Vivek R Yadav; Okhil Nag; Vibhudutta Awasthi
Journal:  Artif Organs       Date:  2014-04-22       Impact factor: 3.094

7.  Improved formulation of liposome-encapsulated hemoglobin with an anionic non-phospholipid.

Authors:  Hrushikesh Agashe; Pallavi Lagisetty; Shanjana Awasthi; Vibhudutta Awasthi
Journal:  Colloids Surf B Biointerfaces       Date:  2009-10-14       Impact factor: 5.268

8.  Anchoring Property of a Novel Hydrophilic Lipopolymer, HDAS-SHP, Post-Inserted in Preformed Liposomes.

Authors:  Rosario Mare; Huining Da; Massimo Fresta; Donato Cosco; Vibhudutta Awasthi
Journal:  Nanomaterials (Basel)       Date:  2019-08-21       Impact factor: 5.076

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.